News

Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025.  COO Valerie Ceva will present at MedInvest Biotech & Pharma Investor Conference in NYC on March 27, 2025.  NORTH BRUNSWICK, N.J., March 18, 2025 (GLOBE NEWSWIRE) — BioAegis Therapeutics, […]

Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.  Rhu-pGSN is an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pathogens. Endogenous levels plummet in ARDS, correlating with disease severity.  NORTH BRUNSWICK, N.J., October 17, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics,

NORTH BRUNSWICK, N.J., September 12, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its Co-founder, Steve Cordovano, will present at the upcoming MedInvest Biotech & Pharma Investor Conference in New York City on September 18 and 19. The presentation, “Conquering Diseases Driven

Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., February 27, 2024 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce site recruitment for BTI-203, a Phase 2 study

Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., October 16, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, is pleased to announce a second partnership

Webinar will take place Tuesday, May 23, 2023 at 2:00 PM Eastern Time NORTH BRUNSWICK, N.J., May 10, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing novel therapies for inflammatory diseases through a portfolio built around plasma gelsolin (pGSN), a highly conserved and abundant endogenous human immune regulatory protein, announces that it

Gelsolin decreased microparticle-driven inflammation and mitigated activation of the NLRP3 inflammasome in type 2 diabetes. Low levels of gelsolin identified in individuals with type 2 diabetes living below poverty. NORTH BRUNSWICK, N.J., April 13, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma

NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human immune regulatory protein, announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for

Company directs clinical effort of its breakthrough therapy to Acute Respiratory Distress Syndrome, for which there are no currently approved treatments. NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and abundant endogenous human

Fund in Europe leads investment to progress commercialization of breakthrough gelsolin therapy to treat inflammatory and infectious diseases. NORTH BRUNSWICK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory, infectious, and degenerative diseases based on a portfolio built around gelsolin technology, announces the completion of a